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ABSTRACT 
This study was conducted to evaluate the efficacy of different market 
samples of Nagakesara in cases of PCOD. In this study 30 patients were 
divided into 3 groups. Group 1: MF Group (Mesua ferrea Linn. powder 
with milk), Group 2: OL Group (Ochrocarpus longifolium Benth & Hook. f; 
powder with milk), Group 3: CT Group (Cinnamomum tamala Nees & 
Ebern powder with milk) and advocated the trial drug with a dosage of 
40-50mg/kg body weight per day for a duration of 3months with a follow 
up of every 15days. Subjective parameters like duration of menstruation, 
gap between two cycles, pain during menstruation, quantity of menstrual 
bleeding, Acne, Hirsutism, Acanthosis nigracans, Obesity are taken and 
results were analyzed statistically before and after treatment. Group 1 
showed that 10% of the patients recovered completely, 55.09% 
recovered moderately and 35% remains unchanged. Group 2 showed 
that 10% of the patients recovered completely, 45.66% moderately and 
44% remains unchanged. Group 3 showed that 0% of the patients 
recovered completely, 52% recovered moderately and 48% remains 
unchanged. Mesua ferrea showed extremely significant result i.e., 
P<0.001 in duration of menstruation (67.85%), gap between two cycles 
(65.62%), quantity of menstrual bleeding (66.66%). All the observations 
related to the total effect of therapy suggests that patients of Group 1 
were well responded to the therapy than the patients of Group 2 and 
Group 3. Conclusion: The present comparative clinical study shows that 
the Amapachana property, the capacity to induce ovulation and reduction 
in the clinical features are more clearly observed in Mesua ferrea Linn. 
than in others. 
 
INTRODUCTION 
Ayurveda is the oldest system of life science, 
health care and cure, its antiquity goes back to the 
Vedas. Traditional medicinal literature appreciated 
their value as nature's gift to mankind for the 
healing of illnesses. 
Diseases of longevity often referred as 
“lifestyle disorders” are posing a great threat to the 
overall health of the society. Among those, Poly 
Cystic Ovarian Disease (PCOD) is considered as one 
of the major burning issue with symptoms like 
irregular menstruation, oligomenorrhoea/ 
amenorrhea, infertility, obesity, hirsutism and acne 
vulgaris. PCOD is one of the most common reasons 
for menstrual irregularities of women of 
reproductive age with 4-12% (12-45yrs old). 
Women develop PCOD during their teenage or child 
bearing years with 5-10%. Worldwide PCOD affects 
up to 6-7% of the total population.[1] 
Nagakesara mentioned in classical works 
has become controversial because of improper 
identification, using the drug with different names 
in different areas and many other contributing 
factors like cheating trade. 
As it is not a single disease it is not possible 
to correlate PCOD with any one of the condition 
explained in the classics. But PCOD can be 
understood with clinical condition like Artava 
Kshaya, Anartava, Nastartava, Kshinartava, Vandhya 
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Yonivyapat, Pushpaghni-Jataharini, Sthoulya and 
Prameha. Recently, there has been an increased in 
interest in the field of PCOD research. Thousands of 
articles were published in the past five years 
concerning the different aspects and relationships 
regarding PCOD. Despite the high and increasing 
incidence of PCOD among the population, there are 
several aspects that remain ambiguous.[2] 
Aims and Objectives 
 Initially this study is aimed at finding out a 
feasible solution in resolving the controversy of 
Nagakesara through its clinical use in PCOD. 
 To procure different market samples of 
Nagakesara. 
 To identify pharmacognostically the source 
plants of the samples. 
 To evaluate the efficacy of samples in cases of 
PCOD. 
Materials and Methods 
Drug 
1. Sample collection 
The three market samples of Nagakesara will be 
collected from three different places i.e., 
Hyderabad, Chennai and Bangalore and they 
will be processed separately for internal 
administration at Srinivasa Ayurveda 
Pharmacy, Tirupathi, into 500mg tablets each. 
2. Processing of the drug 
  Drying of the drug 
  Making powder by using Pulveriser 
  Making tablets by using tablet making machine 
Plan of Study 
1) Criteria for selection of patients 
2) Criteria for diagnosis 
3) Method of research 
 4) Criteria for assessment 
Criteria for Selection of Patients 
Inclusion criteria  
 Female patients suffering from PCOD 
diagnosed through Ultrasonography. 
 Age between 18-40 years. 
 Both married and unmarried females.  
Exclusion criteria 
 Age below 18 years and above 40 years. 
 Primary PCOS. 
 Pituitary abnormalities.  
 Hyper and Hypo Thyroidism. 
 Patients with other disorders of serious 
consideration. 
The Drug 
 The market samples were collected separately 
and powdered well. They were made into 
tablets weighing 500mg each and stored with 
separate marks.  
Criteria for Diagnosis 
All the patients confirming the above said 
inclusion criteria were taken for the study and 
subjected to thorough interrogation, general, 
systemic examinations and investigations and the 
data obtained from them were noted in the 
specially prepared research proforma. Patients 
were selected on the basis of their clinical 
presentation particularly related to Poly Cystic 
Ovarian Disease. The compulsory criteria is being 
the presence of PCOD in Ultrasonography. 
Investigations [3] 
 Laboratory investigations were carried out 
before and after treatment to rule out any other 
pathological conditions as well as to record any 
specific change by the treatment. 
Haematological 
Routine haematological examinations like,  
 Hb%, TLC, DLC, E.S.R.  
 F.B.S. and P.P.B.S. 
 Thyroid profile. 
Urine 
 Routine and microscopic examination. 
Other Blood Tests 
 i) Lipid profile 
 ii) Glucose Tolerance Test 
Special Investigations 
 Ultrasonography (USG)  
 If necessary, Hormonal Assay likes Serum 
Estrogen, Follicle Stimulating Hormone (FSH), 
Luteinizing Hormone (LH), Testosterone etc.  
Method of Research 
The method adopted in the present study is 
a randomized open label clinical trial before and 
after the treatment. The study had a due clearance 
from the Institutional Ethics Committee. 
Informed Consent 
The purpose of the study, nature of the 
study, drugs, the procedures to be carried out and 
the potential risks and benefits were explained to 
the patients in detail in non-technical terms and 
trilingual. Thereafter their written consent was 
taken before starting the procedure. 
Diagnostic Criteria 
Patients were examined clinically and 
details regarding disease starting from history 
taking, physical examination, signs and symptoms 
as mentioned in our classics and allied sciences and 
relevant lab investigations were recorded in a 
specially prepared proforma.  
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 Special clinical proforma for the assessment 
of subjects was prepared, based on criteria of 
selection and parameters. Special grading was given 
to chief symptoms/signs of PCOD. Informed consent 
of all the registered subjects was taken. 
Criteria for Assessment  
 Patients were assessed before and after 
treatment for subjective and objective parameters. 
Subjective Parameters  
 Assessment was totally based on the 
changes in the clinical features of Poly Cystic 
Ovarian Disease and improvement in scoring index 
of Duration of menstruation, gap between two 
cycles, pain during menstruation, acne, hirsutism, 
etc.[6] For all these symptoms, the following 
symptom scores were given depending upon the 
changes seen before and after the treatment. 
Subjective criteria 
Table 1: Showing PCOD grading scale for subjective parameters 
Parameters Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
A) Duration of Menstruation 
a) Menorrhagia 
b) Hypomenorrhea 
 
3–5 days 
3–5 days 
 
6 – 8 days 
2 – 3 days 
 
9 – 12 days 
1 – 2 days 
 
12 – 14 days 
<1 day 
 
>15 days 
Spotting 
B) Gap between two cycles 
a) Oligomenorrhea 
b) Epimenorrhea 
 
25- 35 days 
25 -35 days 
 
36 – 60 days 
20 – 25 days 
 
61 – 90 days 
15 – 20 days 
 
91 – 120 days 
10 – 15 days 
 
>120 days 
<10 days 
C) Pain during Menstruation No pain 
(not 
disturbing 
the normal 
activities) 
Bearable 
pain 
Requirement 
of oral 
analgesics 
Requirement of 
injectable 
Analgesics 
__ 
D) Quantity of Menstrual 
bleeding 
a)Heavy bleeding 
 
b) Scanty bleeding 
 
 
2 pads/ day 
2 pads/ day 
 
 
3 – 4 pads 
/day 
1 pad/day 
 
 
5 – 6 
pads/day 
<1 pad/ day 
 
 
7 pads and above 
Just appears 
__ 
E) Acne No acne 1 or 2 acne 
seen only on 
face (on & 
off) 
Appears on 
face before 
periods and 
subsides 
after periods 
Persistent acne 
on face 
Spreading of 
acne in other 
parts of the 
body 
F ) Hirsutism Normal 
distribution 
of hair 
Mild 
coverage 
(Thin 
distribution 
hair on chin, 
cheeks and 
moustache) 
Moderate 
coverage 
(Thick 
distribution 
of hair on 
chin, cheeks 
and 
moustache) 
Heavy coverage 
(Thick 
distribution of 
hair on chin, 
cheeks and 
moustache and 
other parts of 
body and grows 
rapidly) 
__ 
G ) Acanthosis Nigracans Nil Mild Moderate Severe __ 
H) Obesity (BMI) 20 – 25 
kg/m2 
25 – 30 
kg/m2 
30 – 40 
kg/m2 
More than 40 
kg/m2 
__ 
I ) Ultrasonography      
i) Rt Ovarian volume 5 – 10 ml 11 – 15ml 16 – 20ml 20 – 25ml __ 
ii) Lt Ovarian volume 5 – 10 ml 11 – 15ml 16 – 20ml 20 – 25ml  
iii) Number of follicles <3 4 - 8 9 – 10 11 – 12 >12 
Analysis and interpretation: Assessment is made according to gradation given in case sheet, later the 
result is analysed and interpreted into the hypothesis. 
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Treatment protocol 
 After the proper diagnosis, patients were divided into 3 groups irrespective of their age, socio-
economic status, religion etc. All the patients were given Deepana, Pachana drugs for 7 days. During this 
period, the investigations were carried out and there after the drugs were administered 
Grouping and posology 
Patients were divided randomly into three groups each consisting of ten members. 
 Group 1: MF Group (Mesua ferrea Linn.) 
 Group 2: OL Group (Ochrocarpus longifolium Benth & Hook. f) 
 Group 3: CT Group (Cinnamomum tamala Nees & Ebern) 
 Dose : “40-50 mg/kg (1-3gms app per day) body weight” per day[4] 
 Dosage form : Tablet form 
 Anupana : Milk 
 Duration : 3 months 
 Aushadasevanakalam : Abhaktam 
Follow Up 
Total days of treatment follow up visits: 6 visits 
Post treatment follow up   : 2 visits 
Observation and Results 
Table 2: Statistical Significance of Group 1 (Mesua ferrea) 
 Mean  Sd   Sem Df T 
value 
P 
Value 
Significance 
BT AT BT AT BT AT 
Duration of 
menstruation 
2.80 0.90 1.32 0.32 0.42 0.10 9 5.0186 0.0007 Extremely 
Statistically 
significant 
Gap between 
two cycles 
3.20 1.10 1.03 0.88 0.33 0.28 9 4.8462 0.0009 Extremely 
Statistically 
significant 
Pain during 
menstruation 
2.80 1.00 1.32 0.94 0.42 0.30 9 4.3235 0.0019 Very Statistically 
significant 
Quantity of 
menstrual 
bleeding 
1.50 0.50 0.79 0.50 0.25 0.17 9 1.96 0.002 Extremely 
Statistically 
significant 
Acne 0.50 0.30 0.97 0.67 0.31 0.21 9 1.5 0.167 Statistically 
not significant 
Hirsutism 0.80 0.70 1.03 1.06 0.33 0.33 9 1 0.34 Statistically  
not significant 
Acanthosis 
Nigracans 
1.10 0.80 1.29 1.14 0.41 0.36 9 1.96 0.081 Statistically  
not significant 
Obesity 0.40 0.20 0.84 0.42 0.27 0.13 9 1.5 0.16 Statistically  
not significant 
Mood Changes 0.40 0.20 0.84 0.42 0.27 0.13 9 1.5 0.16 Statistically  
not significant 
U/S Rt Ovary 1.60 0.90 0.84 0.74 0.27 0.23 9 4.5 0.0013 Very 
Statistically 
significant 
U/S Lft Ovary 1.70 1.30 0.82 0.82 0.26 0.26 9 2.44 0.036 Statistically 
significant 
Number of 
follicles 
2.10 2.00 0.57 0.94 0.18 0.30 9 0.3612 0.726 Statistically  
not significant 
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Table 3: Statistical Significance of Group 2 (Ochrocarpus Longifolius) 
Df - 9 Mean  Sd   Sem T value P Value Significance 
 BT AT BT AT BT AT   
Duration of 
menstruation 
1.10 0.70 0.74 0.67 0.23 0.21 2.4495 0.0368 Statistically 
significant 
Gap between two 
cycles 
1.60 1.10 0.70 0.57 0.22 0.18 1.7556 0.0962 Statistically not 
Significant 
Pain during 
menstruation 
1.20 0.60 0.63 0.52 0.20 0.16 2.3238 0.0320 Statistically 
significant 
Quantity of 
menstrual bleeding 
1.80 1 0.42 0.47 0.13 0.15 4.0000 0.0008 Very Statistically 
significant 
Acne 1.20 0.70 0.92 0.67 0.29 0.21 1.3868 0.1825 Not Statistically 
significant 
Hirsutism 1.00 0.80 1.25 1.14 0.39 0.36 0.3750 0.7120 Statistically  
not significant 
Acanthosis 
Nigracans 
1.20 0.50 1.14 0.85 0.36 0.27 1.5609 0.1360 Statistically 
significant 
Obesity 1.50 1.00 1.08 1.25 0.34 0.39 0.9583 0.3506 Statistically 
significant 
Mood Changes 1.00 0.80 0.82 0.79 0.26 0.25 0.5571 0.5843 Statistically  
not significant 
U/S Rt Ovary 1.50 1.30 0.85 0.95 0.27 0.30 0.4966 0.6255 Statistically  
not significant 
U/S Lft Ovary 1.30 1.00 0.67 0.82 0.21 0.26 0.8955 0.3823 Statistically  
not significant 
Number of follicles 1.90 1.50 0.32 0.53 0.10 0.17 2.0580 0.0544 Statistically 
Not Significant 
Table 4: Statistical Significance of Group 3 (Cinnamomum Tamala) 
Df-9 Mean Sd Sem T value P Value Significance 
BT AT BT AT BT AT 
Duration of 
menstruation 
1.20 0.60 1.32 0.84 0.42 0.27 2.7136 0.0239 Statistically 
significant 
Gap between two 
cycles 
2.00 1.30 0.82 0.67 0.26 0.21 3.2796 0.0095 Very Statistically 
Significant 
Pain during 
menstruation 
0.70 0.40 0.95 0.52 0.30 0.16 1.9640 0.0811 Statistically not 
significant 
Quantity of 
menstrual bleeding 
1.30 0.50 0.95 0.53 0.30 0.17 4.0000 0.0031 Very Statistically 
significant 
Acne 0.50 0.30 0.53 0.48 0.17 0.15 1.500 0.1679 Statistically not 
significant 
Hirsutism 1.00 0.70 1.05 0.95 0.33 0.30 1.9640 0.0811 Statistically not 
significant 
Acanthosis 
Nigracans 
1.10 0.50 1.10 0.53 0.35 0.17 2.2500 0.0510 Statistically not 
significant 
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Obesity 1.30 1.00 0.95 0.82 0.30 0.26 1.1523 0.2789 Statistically not 
significant 
Mood Changes 1.20 0.80 0.92 0.79 0.29 0.25 1.5000 0.1679 Statistically not 
significant 
 U/S Rt Ovary 1.40 1.20 0.52 0.79 0.16 0.25 1.500 0.1679 Statistically not 
significant 
U/S Lft Ovary 2.20 1.70 0.63 0.67 0.20 0.21 3.000 0.0150 Statistically 
significant 
Number of follicles 1.70 1.50 0.48 0.53 0.15 0.17 1.5000 0.1679 Statistically not 
significant 
Table 5: Overall result of the study – % of relief parameters wise result in Group 1, Group 2 & Group 3 
Parameters  Group 1  Group 2 Group 3 
Duration Of Menstruation  67.85% 36.36% 50% 
Gap Between Two Cycles   65.62% 31.25% 35% 
Pain During Menstruation  64.28% 50% 42.8% 
Quantity of Menstrual Bleeding  66.66% 44.44% 61.53% 
Acne  40% 41.6% 40% 
Hirsutism  12.5% 20% 30% 
Acanthosis Nigracans  27.2% 58.3% 54.5% 
Obesity  50% 33.33% 23% 
Mood Changes  50% 20% 33.3% 
U/S Right Ovary  43.75% 13.33% 14.2% 
U/S Left Ovary  23.52% 23% 22.7% 
Number Of Follicles  4.76% 21% 11.7% 
Graph No 1. Statistical Comparison of Group 1 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
%
 o
f 
re
lie
f
Nikath. S et al. Clinical Study of Market Samples of Nagakesara in the Management of Poly Cystic Ovarian Disease (PCOD)  
AYUSHDHARA | May - June 2018 | Vol 5 | Issue 3  1711 
Graph No 2. Statistical Comparison of Group 2 
 
Graph No 3. Statistical Comparison of Group 3 
 
Table 6: Improvement Wise Result in Group 1, Group 2 & Group 3 
Overall Effect Group 1 Group 2 Group 3 
Completely relieved 10% 10% 0% 
Moderately relieved 55.09% 45.66% 52% 
Unchanged 35% 44% 48% 
DISCUSSION
Interpretation of results in Group 1 
Nagakesara in Group 1 (Mesua ferrea Linn 
with milk) has shown following results. 
 Mesua ferrea shown extremely significant result 
i.e., P<0.001 in duration of menstruation 
(67.85%), gap between two cycles (65.62%), 
quantity of menstrual bleeding (66.66%). This 
proves that Mesua ferrea Linn. can be utilized to 
promote menstruation and correct the cycles.  
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 Mesua ferrea shown very significant result i.e., 
P=0.001 in Pain during menstruation (64.28%), 
U/S right ovarian volume (43.75%). As Artava is 
properly or timely formed which was proved by 
above result, so probably Suddha artava 
lakshanas are also associated. 
 Mesua ferrea shown insignificant result i.e., 
P>0.05 in acne (40%), hirsutism (12.5%), 
Acanthosis nigracans (27.2%), obesity (50%), 
Mood changes (50%), number of follicles 
(4.76%). These all features occur due to 
increased androgen levels or Sukradushti. The 
drug might be effective in clearing the Rasa- 
Raktavaha channels only or dosage of drug and 
duration of course might be insufficient to bring 
complete relief in the above features. 
Interpretation of results in Group 2 
Surapunnaga in Poly cystic ovarian disease in 
Group - 2 (Ochrocarpus longifolius Benth & Hook f. 
with milk) has shown following results. 
 Ochrocarpus longifolius has shown very 
significant result i.e., P=0.001 in quantity of 
menstrual bleeding (44.44%). 
 Ochrocarpus longifolius has shown significant 
result i.e., P<0.05 in duration of menstruation 
(36.36%), pain during menstruation (50%), acne 
(41.6%), Acanthosis nigracans (58.3%), obesity 
(33.33%). 
 Ochrocarpus longifolius shown insignificant 
result i.e., P>0.05 in gap between two cycles 
(31.25%), hirsutism (20%), mood changes 
(20%), U/S right ovary (13.33%), U/S left ovary 
(23%), number of follicles (21%). Though this 
has shown very significant result in quantity of 
menstruation, as this is not having the equivalent 
qualities like Mesua ferrea, it could not show 
significant improvement in other clinical 
features like interval between two cycles, 
duration of menstruation, pain etc. 
Interpretation of results in Group 3 
Tamalapatra in Poly Cystic Ovarian Disease 
in Group - 3 (Cinnamomum tamala Nees & ebern 
with milk) has shown following results. 
 Cinnamomum tamala has shown very significant 
result i.e., P=0.001 in gap between two cycles 
(35.44%). 
 Cinnamomum tamala has shown significant 
result i.e., P<0.05 in duration of menstruation 
(50%), quantity of menstrual bleeding (61.53%), 
U/S left ovary (20.85%). 
 Cinnamomum tamala shown insignificant result 
i.e., P>0.05 pain during menstruation (42.8%), 
acne (40%), Acanthosis Nigracans (54.5%), 
obesity (23%), hirsutism (30%), mood changes 
(33%), U/S right ovary (13.33%), U/S left ovary 
(22.7%) number of follicles (11.7%). 
 Cinnamomum could be able to show better 
efficacy only in the interval of menstrual cycle 
which is also very less i.e., 35.44%, but showed 
significant efficacy in duration and quantity of 
menstruation upto some extent. These results 
indicate that cinnamomum also has the property 
of in Artavajanana, but this is not equivalent to 
Mesua ferrea. 
Overall effect of the clinical trial 
 The overall effect of the clinical trial on Group 1 
(Nagakesara with milk) shows that patients 
(10%) were completely cured, (31.8%) were 
cured moderately and (35%) were unchanged. 
 The overall effect of the clinical trial on Group 2 
(Surapunnaga with milk) (23.86%) were 
completely cured, (31.8%) were cured 
moderately, (44%) were unchanged. 
 The overall effect of the clinical trial on Group 3 
(Tamalapatra with milk) (19%) were completely 
cured, (32%) were cured moderately (48%) 
were unchanged. 
Discussion on overall effect 
As per the clinical study, there are very few 
completely relieved patients even in 1st and 2nd 
group. Though there is highly significant 
improvement in subjective parameters, as per 
ultrasound diagnosis, the improvement was non- 
significant. As ultrasound investigation is 
considered the main diagnostic criteria in the 
present study, this result was observed. In the 1st 
group, one patient conceived after the treatment. 
She was totally relieved from PCOD as observed 
through Ultrasonography. In the 2nd group also, in 
one patient, Ultrasound report appeared normal. 
All the observations related to the total 
effect of therapy suggests that patients of Group 1 
were well responded to the therapy than the 
patients of Group 2 and Group 3.  
The present clinical study proved that 
Nagakesara is one of the best Artavajanaka and is 
effective in PCOD. 
As per classics, Nagakesara is the best 
Amapachaka and it is used clinically as an ovulation 
inducing drug. The Nidana of PCOD also gives an 
inference that Vata and Kaphadushti are more in 
this disease which results in Amotpatti and there by 
the disease PCOD is manifested.[5] 
As the disease PCOD is a syndrome complex, 
it is very difficult to assess the efficacy with single 
Ayurvedic drug. But the present drug Nagakesara 
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has proved that it has significant efficacy in the 
management of PCOD. 
The present comparative clinical study 
shows that the Amapachana property, the capacity 
to induce ovulation and reduction in the clinical 
features are more clearly observed in Mesua ferrea 
Linn. than in others. 
In context to induction of ovulation or 
PCOD, it is better to use Mesua ferrea Linn. Along 
with this drug, if other drugs that have synergetic 
action in induction of ovulation are combined, the 
efficacy may be enhanced. 
On par with Mesua ferrea Linn. the 
remaining two drugs cannot be considered as 
substitutes, particularly in induction of ovulation or 
in the management of PCOD. But Surapunnaga 
(Ochrocarpus longifolius Benth & Hook f.), can be 
used as an adjuvant to Mesua ferrea Linn. in 
Acanthosis nigracans. The synergetic action of these 
two are proved, the combination may give a better 
result in PCOD. 
CONCLUSION 
 PCOD consists of gross symptoms like Anartava, 
Sthoulya, Vandhyatwa, Yavana Pidaka etc. 
 The total number of patients was divided into 
three groups adjusting each 10 in a Group. They 
were grouped into Group 1, 2 & 3. 
 The patients of Group 1 were administered the 
powdered drug of Mesua ferrea Linn. The 2nd 
Group was given Ochrocarpus longifolius Benth 
& Hook.f, and the 3rd Group was given the Buds 
of Cinnamomum tamala Nees & Ebern. 
 The treatment continued for all the groups for a 
period of 3 months with a follow up of one more 
month and the results were tabulated. 
 In the present study Group 1 (Mesua ferrea 
Linn. with milk) shows that 10% of the patients 
recovered completely, 55.09% recovered 
moderately and 35% remains unchanged. 
 Group 2 (Ochrocarpus longifolius Benth & Hook, 
f. with milk) shows that 10% of the patients 
recovered completely, 45.66% moderately and 
44% remains unchanged. 
 Group 3 (Cinnamomum tamala Nees & Ebern 
with milk) shows that 0% of the patients 
recovered completely, 52% recovered 
moderately and 48% remains unchanged. 
 On proper evaluation of the results, Mesua 
ferrea Linn. is proved to be more effective 
clinically in cases of Artava vikara, which we 
have equated with PCOD. 
 Hence the final conclusion depending up on 
both, the literature study and clinical study, the 
exact source of Nagakesara can be equated with 
the flowers of Mesua ferrea Linn. The next place 
in case of non availability of the above drug goes 
to Ochrocarpus Longifolius Benth & Hook.f, 
finally the flower buds of Cinnamomum tamala 
Nees & Ebern, which is known as black variety 
in the markets may be used in any case of 
bleeding disorders like Krchrartava, Arshas and 
Pradara. 
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